Study guide

23.2 Perioperative Crises: Malignant Hyperthermia and Severe Anaphylaxis

EDAIC Part I European Diploma in Anaesthesiology and Intensive Care

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: The EDAIC Part I Examination

1.1 EDAIC Part I Exam Format, Scoring and Multiple True/False Strategy

2 Chapter 2: Anatomy for Anaesthesia and Intensive Care

2.1 Functional Anatomy of the Upper Airway, Larynx, and Tracheobronchial Tree 2.2 Neuraxial Anatomy: Spine, Spinal Cord, Meninges, and Spaces 2.3 Vascular Anatomy for Central and Peripheral Cannulation 2.4 Peripheral Nerve Plexuses and Autonomic Nervous System Pathways 2.5 Thoracic Anatomy: Chest Wall, Intercostal Spaces, Pleura, Mediastinum and Heart

3 Chapter 3: Respiratory and Cardiovascular Physiology

3.1 Respiratory Mechanics, Lung Volumes, and Work of Breathing 3.2 Ventilation-Perfusion Relationships, Shunt, and Gas Exchange 3.3 Control of Breathing, Hypoxia, Altitude and Hyperbaric Physiology 3.4 Cardiac Cycle, Electrophysiology, and Ventricular Function 3.5 Vascular Resistance, Microcirculation, and Systemic Hemodynamics

4 Chapter 4: Neurophysiology, Renal, Hepatic and Acid-Base Physiology

4.1 Cerebral Blood Flow, Intracranial Pressure, and CSF Dynamics 4.2 Renal Physiology, Glomerular Filtration, and Tubular Transport 4.3 Hepatic Blood Flow, Metabolism, and Clearance 4.4 Acid-Base Regulation, Buffering Systems, and Stewart Approach

5 Chapter 5: Endocrine and Haematological Physiology

5.1 Endocrine Physiology and the Neuroendocrine Stress Response 5.2 Haemostasis Physiology, Coagulation Testing and Inherited Bleeding Disorders

6 Chapter 6: Special Patient Physiology: Maternal, Paediatric and Geriatric

6.1 Maternal Physiological Adaptations to Pregnancy and Uteroplacental Flow 6.2 Neonatal and Paediatric Physiological Differences 6.3 Physiological Changes of Ageing and Thermoregulation

7 Chapter 7: General Pharmacological Principles and Inhalational Anaesthetics

7.1 Pharmacokinetic Principles, Compartmental Models, and Clearance 7.2 Pharmacodynamic Mechanisms, Receptor Theory, and Drug Interactions 7.3 Physical Properties, Uptake, and Distribution of Volatile Anaesthetics 7.4 Minimum Alveolar Concentration (MAC), Organ Effects, and Toxicity

8 Chapter 8: Intravenous Agents, Neuromuscular Blockade and Analgesics

8.1 Intravenous Induction Agents: Propofol, Etomidate, Ketamine, and Barbiturates 8.2 Neuromuscular Blocking Agents: Depolarizing and Non-Depolarizing Drugs 8.3 Neuromuscular Monitoring and Reversal: Anticholinesterases and Sugammadex 8.4 Opioid Pharmacology, Receptors, and Non-Opioid Analgesic Agents

9 Chapter 9: Cardiovascular Drugs, Autonomic Pharmacology and Local Anaesthetics

9.1 Inotropes, Vasopressors, and Inodilators in Perioperative Care 9.2 Antiarrhythmic, Antihypertensive, and Beta-Adrenergic Antagonist Drugs 9.3 Local Anaesthetic Pharmacology, Toxicity (LAST), and Lipid Emulsion Therapy

10 Chapter 10: Haematological and Internal Medicine Pharmacology

10.1 Anticoagulant, Antiplatelet and Haemostatic Drugs and Their Reversal 10.2 Internal Medicine Drugs: Endocrine, Respiratory, Psychiatric and Antiepileptic Agents and Their Anaesthetic Interactions

11 Chapter 11: Physics, Clinical Measurement and Medical Equipment

11.1 Physical Gas Laws, Fluid Dynamics, and Resistance Principles 11.2 Anaesthetic Machines, Gas Supply Pipelines, Cylinders, and Safety Mechanisms 11.3 Breathing Systems, Vaporizer Mechanics, and Scavenging Systems 11.4 Invasive and Non-Invasive Hemodynamic and Respiratory Monitoring

12 Chapter 12: Electrical Safety, Temperature, Humidity and Gas Analysis

12.1 Electricity, Electrical Safety, Diathermy, Defibrillation, Implanted Devices and Fire 12.2 Temperature Measurement, Humidity, Gas Analysis and SI Units

13 Chapter 13: Biostatistics, Clinical Trials and Evidence Appraisal

13.1 Descriptive Statistics, Distributions, and Parametric vs Non-Parametric Tests 13.2 Hypothesis Testing, Power, Type I/II Errors, and Confidence Intervals 13.3 Clinical Study Designs, Bias, and Diagnostic Test Performance (Sensitivity, Specificity, ROC)

14 Chapter 14: General Anaesthesia, Preoperative Evaluation and Airway Management

14.1 Preoperative Risk Assessment, Cardiovascular Risk Indices, and Fasting Guidelines 14.2 The Difficult Airway: Assessment, Algorithms, and Rescue Oxygenation 14.3 Intraoperative Fluid Therapy, Goal-Directed Hemodynamics, and Blood Conservation 14.4 Post-Anaesthesia Care Unit (PACU) Management, Emergence, and Postoperative Nausea/Vomiting

15 Chapter 15: Coexisting Disease and Preoperative Investigations

15.1 Interpreting Investigations: ECG, Chest Radiograph, Lung Function and Blood Tests 15.2 Coexisting Disease I: Asthma, COPD, Obstructive Sleep Apnoea, Obesity, Liver and Renal Disease 15.3 Endocrine Disease and Emergencies: Diabetes, DKA and HHS, Thyroid, Adrenal, Phaeochromocytoma and Carcinoid 15.4 Coexisting Disease II: Neuromuscular and Neurological Disease

16 Chapter 16: Subspecialty Anaesthesia: Cardiothoracic, Vascular and Neuroanaesthesia

16.1 Anaesthesia for Cardiac Surgery and Cardiopulmonary Bypass Management 16.2 Thoracic Anaesthesia, One-Lung Ventilation, and Major Vascular Surgery 16.3 Neuroanaesthesia: Craniotomy, Sitting Position, and Traumatic Brain Injury

17 Chapter 17: Obstetric, Paediatric and Ambulatory Anaesthesia

17.1 Obstetric Analgesia and Anaesthesia: Labour, Caesarean Delivery, and High-Risk Conditions 17.2 Paediatric Anaesthesia: Induction, Airway Management, and Emergencies 17.3 Ambulatory Day-Surgery Selection, Premedication, and Elderly Patient Anaesthesia

18 Chapter 18: Anaesthetic Complications and Specialty Settings

18.1 Anaesthetic Complications: Accidental Awareness, Aspiration, Positioning Injuries, Visual Loss and Dental Damage 18.2 Anaesthesia for ENT and Laser Airway Surgery, Ophthalmic Surgery, and Laparoscopic and Robotic Surgery

19 Chapter 19: Regional Anaesthesia and Acute/Chronic Pain Management

19.1 Neuraxial Techniques: Spinal, Epidural, and Caudal Anaesthesia 19.2 Upper and Lower Limb Peripheral Nerve and Fascial Plane Blocks 19.3 Multimodal Acute Postoperative Pain Management and ERAS Pathways 19.4 Chronic and Neuropathic Pain Syndromes and Interventional Management 19.5 Palliative Symptom Control, Psychological Aspects of Pain and Multidisciplinary Pain Management

20 Chapter 20: Intensive Care Medicine: Ventilation, Shock and Organ Support

20.1 Acute Respiratory Distress Syndrome (ARDS) and Mechanical Ventilation Strategies 20.2 Sepsis-3 Definitions, Septic Shock, and Hemodynamic Resuscitation 20.3 Acute Kidney Injury, Indications for Dialysis, and Continuous Renal Replacement Therapy 20.4 ICU Sedation, Delirium, Weaning, and Brain Death Determination

21 Chapter 21: Intensive Care Medicine: Admission, Nutrition, Infection and Electrolytes

21.1 ICU Admission, Severity Scoring, Nutrition and Routine Prophylaxis 21.2 Antimicrobial Therapy, Stewardship and ICU-Acquired Infections 21.3 Electrolyte Disorders: Sodium, Potassium, Calcium, Magnesium and Phosphate

22 Chapter 22: Intensive Care and Emergency Medicine: Neurocritical Care, Poisoning and Cardiorespiratory Emergencies

22.1 Neurocritical Care: Subarachnoid Haemorrhage, Stroke, Status Epilepticus and Acute Neuromuscular Failure 22.2 Acute Poisoning: Toxidromes, Decontamination and Specific Antidotes 22.3 Acute Cardiorespiratory Emergencies: Pulmonary Embolism, Acute Severe Asthma and COPD, Non-Invasive Support and Acute Heart Failure

23 Chapter 23: Resuscitation, Perioperative Emergencies and Professional Ethics

23.1 Advanced Life Support (ALS) Guidelines and Perioperative Cardiac Arrest 23.2 Perioperative Crises: Malignant Hyperthermia and Severe Anaphylaxis 23.3 Major Trauma, Hemorrhagic Shock, and Massive Transfusion Protocols 23.4 Professional Ethics, Informed Consent, Patient Safety, and Helsinki Declaration

24 Chapter 24: Newborn, Paediatric and Obstetric Emergencies

24.1 Newborn Life Support and Paediatric Life Support 24.2 Obstetric Emergencies: Maternal Collapse, Amniotic Fluid Embolism, Uterine Inversion and Resuscitative Hysterotomy

25 Chapter 25: Burns, Environmental Emergencies and Patient Transport

25.1 Burns, Inhalation Injury, Drowning, Hypothermia, Heat Illness and Decompression Illness 25.2 Prehospital Care and Intra- and Inter-Hospital Transport of the Critically Ill

23.2 Perioperative Crises: Malignant Hyperthermia and Severe Anaphylaxis

Key Takeaways Explain This Topic AI

Malignant hyperthermia (MH) is an autosomal dominant pharmacogenetic channelopathy predominantly caused by mutations in the ryanodine receptor 1 gene (RYR1, >70%), triggered by all volatile anaesthetics and suxamethonium.

The earliest and most reliable sign of MH is an unexplained, dramatic elevation in ETCO2 refractory to hyperventilation; masseter muscle rigidity occurs in ~1% of children after suxamethonium, whereas hyperthermia is a late finding.

Emergency treatment of MH under European Malignant Hyperthermia Group (EMHG) guidelines requires trigger cessation, hyperventilation with 100% O2 at >= 10-15 L/min, rapid IV dantrolene (2.5 mg/kg bolus, repeated to >10 mg/kg), hyperkalemia correction, active cooling discontinued at 38.5°C, and maintaining diuresis >1-2 mL/kg/h.

Leading perioperative anaphylaxis culprits vary by country: neuromuscular blocking agents cause about 50-60% of cases in French series, whereas antibiotics led the UK NAP6 audit (about 47%, mainly teicoplanin and co-amoxiclav) ahead of NMBAs (about one-third); first-line therapy is prompt intravenous epinephrine, titrated by clinical severity, combined with 20-30 mL/kg crystalloid loading and serial serum tryptase sampling.

Last updated: October 2026

23.2 Perioperative Crises: Malignant Hyperthermia and Severe Anaphylaxis

Intraoperative crises such as Malignant Hyperthermia (MH) and acute perioperative anaphylaxis represent life-threatening emergencies that develop precipitously under anaesthesia. Both conditions feature rapid cardiovascular collapse and metabolic decompensation, requiring instant recognition, immediate pharmacological intervention, and adherence to standardized European clinical guidelines.

1. Malignant Hyperthermia: Genetics and Molecular Pathophysiology

Malignant Hyperthermia is an inherited pharmacogenetic channelopathy of skeletal muscle characterized by hypermetabolism triggered by halogenated volatile anaesthetics or depolarizing neuromuscular blockers.

Molecular Genetics

Transmission: Autosomal dominant with variable penetrance and expressivity. Incidence is approximately 1 in 10,000 to 1 in 50,000 anaesthetics.

RYR1 Gene: Mutations in the RYR1 gene on chromosome 19q13.1 account for over 70% of MH-susceptible families. RYR1 encodes the skeletal muscle Ryanodine Receptor 1, the sarcoplasmic reticulum calcium release channel.

CACNA1S Gene: Mutations in CACNA1S on chromosome 1q32 account for < 2 – 3 % <2\text{--}3\% < 2 – 3% of cases. It encodes the α 1 \alpha_1 α 1 ​ -subunit of the L-type voltage-gated calcium channel (dihydropyridine receptor / DHPR).

Associated Myopathies: MH susceptibility is genetically linked to Central Core Disease and King-Denborough Syndrome .

Critical Distinction: Duchenne and Becker Muscular Dystrophies are NOT malignant hyperthermia. In dystrophinopathies, exposure to suxamethonium precipitates massive rhabdomyolysis and life-threatening hyperkalemic cardiac arrest due to sarcolemmal fragility, not abnormal RyR1 calcium channel kinetics. Halogenated volatiles can trigger volatile-induced rhabdomyolysis (anesthetic-induced rhabdomyolysis / AIR) in DMD, but this does not represent true hypermetabolic MH.

Pathophysiological Cascade

In MH-susceptible skeletal muscle, triggering agents induce conformational changes in mutated RyR1 channels, causing uncontrolled, sustained efflux of calcium from the sarcoplasmic reticulum into the myoplasm. Intracellular calcium concentrations surge twenty-fold:

Sustained troponin-C activation drives uninhibited actin-myosin cross-bridge cycling and profound muscle contraction / rigidity .

Sarcoplasmic reticulum C a 2 + -ATPase Ca^{2+}\text{-ATPase} C a 2 + -ATPase (SERCA) and myocellular pumps work at maximum capacity to re-sequester calcium, consuming massive reserves of adenosine triphosphate (ATP).

Accelerating glycogenolysis and oxidative phosphorylation exhaust oxygen reserves, shifting to anaerobic metabolism, massive lactic acid generation, and mixed metabolic and respiratory acidosis .

Heat generation from uncoupled aerobic/anaerobic ATP hydrolysis overwhelms thermoregulatory capacity, precipitating fulminant hyperthermia .

Cellular energy exhaustion leads to myocyte membrane rupture, releasing vast quantities of potassium, myoglobin, and creatine kinase (CK) into the circulation.

2. Triggering Agents and Clinical Manifestations +------------------------------------+------------------------------------+

  • | TRIGGERING AGENTS | SAFE AGENTS |
  • +------------------------------------+------------------------------------+
  • | - All volatile inhalational | - Intravenous induction agents |
  • | anaesthetics (sevoflurane, | (propofol, etomidate, ketamine, |
  • | desflurane, isoflurane, | thiopental, methohexital) |
  • | halothane, enflurane) | - All non-depolarizing NMBAs |
  • | - Depolarizing muscle relaxants | (rocuronium, vecuronium, |
  • | (suxamethonium / succinylcholine)| cisatracurium, atracurium) |
  • | | - All opioids, local anaesthetics, |
  • | | nitrous oxide, benzodiazepines |
  • +------------------------------------+------------------------------------+
  • Clinical Progression and Warning Signs

Earliest and Most Sensitive Sign: An unexplained, dramatic surge in End-Tidal Carbon Dioxide ( E T CO 2 ET\text{CO}_2 ET CO 2 ​ ) that is completely refractory to massive increases in minute ventilation ( E T CO 2 ET\text{CO}_2 ET CO 2 ​ doubling or tripling to > 75 – 100 mmHg >75\text{--}100\text{ mmHg} > 75 – 100 mmHg ). Sinus tachycardia and tachypnea (in spontaneous breathers) accompany this early hypercapnia.

Masseter Muscle Rigidity (MMR): Acute spasm of the jaw muscles ("jaws of steel") occurring immediately following suxamethonium administration, preventing laryngoscopy. MMR occurs in approximately 1% of paediatric patients receiving suxamethonium. If MMR is accompanied by generalized axial or peripheral muscle rigidity, it indicates fulminant MH. If MMR occurs in isolation without other hypermetabolic signs, the procedure should ideally be aborted; if emergency surgery is required, anaesthesia must be switched immediately to clean non-triggering intravenous drugs with intensive monitoring.

Intermediate Signs: Cutaneous mottling, cyanosis, unstable hemodynamic arrhythmias (ventricular ectopy, peaked T waves from hyperkalemia), and generalized muscular rigidity.

Late Signs: Hyperthermia with core body temperatures climbing at 1 – 2 °C 1\text{--}2\text{°C} 1 – 2 °C every 5 minutes (often exceeding 41 – 42 °C 41\text{--}42\text{°C} 41 – 42 °C ), gross myoglobinuria (burgundy/cola-colored urine), profound mixed acidosis ( p H < 7.10 pH < 7.10 p H < 7.10 , base excess < − 10 mmol/L < -10\text{ mmol/L} < − 10 mmol/L ), disseminated intravascular coagulation (DIC), and hyperkalemic cardiac arrest.

  • 3. Emergency Management: European Malignant Hyperthermia Group Protocol
  • Successful management requires immediate execution of the EMHG protocol: [ SUSPECTED MALIGNANT HYPERTHERMIA ]
  • |
  • +-------------------+-------------+-------------+-------------------+
  • | | | |
  • [ Stop Triggers ] [ Hyperventilate ] [ Dantrolene ] [ Treat Complications ]
  • Turn off gas - 100% O2 - 2.5 mg/kg IV - Treat K+ (Calcium, Insulin)
  • Alert surgeon - Max flow (>=10-15 L/min) rapid bolus - Cool (stop at 38.5°C)
  • Call MH cart - Insert charcoal filters - Repeat q5-10min - Diuresis >1-2 mL/kg/h

Cease Triggers and Call for Assistance: Discontinue all volatile anaesthetics and suxamethonium immediately. Alert the surgical team to conclude or abort the procedure. Call for the MH emergency trolley and summon additional staff.

Hyperventilate with 100% Oxygen: Increase fresh gas flows to maximum ( ≥ 10 – 15 L/min \ge 10\text{--}15\text{ L/min} ≥ 10 – 15 L/min ) using 100% O 2 \text{O}_2 O 2 ​ . Hyperventilate the patient to two to three times predicted minute ventilation to clear carbon dioxide. Insert activated charcoal vapor filters directly onto the inspiratory and expiratory limbs of the breathing circuit. Do not waste time replacing the anaesthetic machine or ventilator during active crisis.

Administer Dantrolene Sodium:

Initial Bolus: Administer 2.5 mg/kg 2.5\text{ mg/kg} 2.5 mg/kg IV rapidly.

Repeat Dosing: Repeat boluses of 1 – 2.5 mg/kg 1\text{--}2.5\text{ mg/kg} 1 – 2.5 mg/kg every 5 to 10 minutes until hypermetabolism, tachycardia, and rigidity subside. Total cumulative doses may exceed 10 mg/kg 10\text{ mg/kg} 10 mg/kg .

Mechanism of Action: Dantrolene binds specifically to the RyR1 receptor , blocking the release of channel-mediated calcium from the sarcoplasmic reticulum without depressing cardiac excitation-contraction coupling.

Formulations: Dantrium (20 mg lyophilized powder with 3 g mannitol per vial, requiring reconstitution in 60 mL sterile water per vial; cumbersome and slow) versus Ryanodex (250 mg nanocrystal suspension requiring only 5 mL sterile water; reconstituted in < 1 minute <1\text{ minute} < 1 minute , US) and Agilus (120 mg per vial reconstituted with 20 mL water, available in Europe), which reduce the number of vials to prepare.

Manage Life-Threatening Hyperkalemia:

10% Calcium chloride 10 mg/kg 10\text{ mg/kg} 10 mg/kg IV (or 10% calcium gluconate 30 mg/kg 30\text{ mg/kg} 30 mg/kg ) to stabilize myocardial membrane excitability.

Regular insulin 10 units with 50 mL 50\text{ mL} 50 mL of 50% glucose (or 25 g 25\text{ g} 25 g dextrose).

Sodium bicarbonate 1 – 2 mmol/kg 1\text{--}2\text{ mmol/kg} 1 – 2 mmol/kg IV for refractory acidosis.

Absolute Contraindication: Never administer calcium channel blockers (verapamil, diltiazem) with dantrolene. The combination precipitates fatal hyperkalemic myocardial depression and cardiovascular collapse.

Active Cooling Measures: Infuse cold ( 4 °C 4\text{°C} 4 °C ) normal saline IV ( 1000 mL 1000\text{ mL} 1000 mL boluses); apply surface ice packs to axillae, groin, and neck; perform cold cavity lavage. Stop active cooling once core temperature drops to 38.5 °C 38.5\text{°C} 38.5 °C to avoid hypothermic overshoot and coagulopathy.

Renal Protection: Maintain urine output > 1 – 2 mL/kg/h >1\text{--}2\text{ mL/kg/h} > 1 – 2 mL/kg/h with IV fluids, mannitol ( 0.5 g/kg 0.5\text{ g/kg} 0.5 g/kg ), and furosemide to prevent renal tubular precipitation of myoglobin casts and acute tubular necrosis.

Diagnostic Confirmation: The gold standard for definitive diagnosis is the In Vitro Contracture Test (IVCT) (in Europe, per EMHG protocol) or Caffeine-Halothane Contracture Test (CHST in North America), requiring a fresh muscle biopsy from the vastus medialis exposed to halothane and caffeine in an organ bath, supplemented by comprehensive RYR1 genetic sequencing.

4. Severe Perioperative Anaphylaxis: Mechanisms and Culprits

Perioperative hypersensitivity reactions occur in approximately 1 in 10,000 surgical procedures. Due to patient draping and general anaesthesia, classic cutaneous signs are often concealed, presenting primarily as sudden cardiovascular collapse or catastrophic bronchospasm.

Immunological vs Non-Immunological Mechanisms

IgE-Mediated Anaphylaxis (Type I Hypersensitivity): Requires prior immunological sensitization. Allergen-specific IgE bound to high-affinity F c ε R I Fc\varepsilon RI F c εR I receptors on tissue mast cells and basophils cross-links upon antigen re-exposure, triggering explosive release of preformed mediators (histamine, tryptase, chymase) and de novo synthesis of leukotrienes ( L T C 4 , L T D 4 LTC_4, LTD_4 L T C 4 ​ , L T D 4 ​ ), prostaglandins ( P G D 2 PGD_2 PG D 2 ​ ), and platelet-activating factor (PAF).

Non-IgE-Mediated Hypersensitivity (Anaphylactoid / Pseudoallergic): Direct, non-immune activation of mast cells and basophils. A prominent mechanism is activation of the Mas-related G protein-coupled receptor X2 (MRGPRX2) by basic compounds such as neuromuscular blockers (atracurium, mivacurium), vancomycin, fluoroquinolones, and opioids. It is clinically indistinguishable from IgE-mediated anaphylaxis during the acute crisis.

Primary Offending Agents in European Practice

The leading culprits differ between countries and over time, so local data matter.

Neuromuscular Blocking Agents (NMBAs): Responsible for about 50-60% of IgE-mediated perioperative anaphylaxis in French and other continental European series, but about one-third of cases in the UK NAP6 audit (2018). The allergenic epitope is the quaternary ammonium group , which is ubiquitous in cosmetics, soaps, and disinfectants (explaining anaphylaxis on first known exposure). High cross-reactivity (60-70%) exists between different NMBAs. Suxamethonium and rocuronium exhibit the highest reporting rates.

Antibiotics: The most common identified cause in NAP6 (about 47% , chiefly teicoplanin and co-amoxiclav) and about 15-20% in French series. Beta-lactams (penicillins and cephalosporins like cefazolin) and teicoplanin are the main culprits.

Chlorhexidine: About 9% of NAP6 cases; increasingly recognized as a major occult allergen present in surgical skin preps, central venous catheter coatings, urethral lubricating gels, and dressings.

Patent Blue V / Isosulfan Blue Dyes: About 4.5% of NAP6 cases; used for sentinel lymph node localization in breast cancer and melanoma. Reactions characteristically develop 15 – 45 minutes 15\text{--}45\text{ minutes} 15 – 45 minutes after intradermal injection, often presenting with blue-tinged wheals and severe hypotension. It also causes optical interference with pulse oximetry, yielding false-positive desaturation.

Latex: Natural rubber latex proteins; historically dominant, now reduced due to latex-free environments.

Colloid Plasma Expanders and Protamine: Gelatins (Gelofusine) and protamine (higher risk in patients with fish allergies or prior NPH insulin use).

5. Clinical Grading and Resuscitation of Severe Anaphylaxis +-------------+--------------------------------------------------------------+

  • | GRADE | CLINICAL MANIFESTATIONS |
  • +-------------+--------------------------------------------------------------+
  • | Grade I | Cutaneous-mucosal signs: erythema, urticaria, angioedema |
  • +-------------+--------------------------------------------------------------+
  • | Grade II | Moderate multi-organ signs: hypotension, tachycardia, |
  • | | cough, mild bronchospasm, cutaneous signs |
  • +-------------+--------------------------------------------------------------+
  • | Grade III | Life-threatening shock: severe hypotension, marked |
  • | | bronchospasm, elevated peak airway pressure, desaturation |
  • +-------------+--------------------------------------------------------------+
  • | Grade IV | Circulatory arrest: PEA or asystole |
  • +-------------+--------------------------------------------------------------+
  • Resuscitation Protocol

Discontinue Suspected Allergen: Immediately halt administration of the suspected offending infusion (antibiotic, colloid, dye, muscle relaxant). Turn off volatile anaesthetic agents.

Airway and Oxygenation: Deliver 100% O 2 \text{O}_2 O 2 ​ . Intubate early if angioedema threatens the upper airway; provide positive pressure ventilation if bronchospasm compromises gas exchange.

First-Line Drug: Epinephrine (Adrenaline):

Epinephrine is the definitive life-saving medication. Alpha-1 vasoconstriction counteracts massive systemic vasodilation and mucosal edema; beta-1 inotropy/chronotropy restores coronary perfusion; beta-2 receptor stimulation reverses bronchospasm and elevates intracellular cAMP, halting further mast cell degranulation.

Grade II: Titrated boluses of 10 – 20 μ g 10\text{--}20\text{ }\mu\text{g} 10 – 20 μ g IV ( 0.1 – 0.2 mL 0.1\text{--}0.2\text{ mL} 0.1 – 0.2 mL of 1:10,000 dilution).

Grade III: Titrated boluses of 50 – 100 μ g 50\text{--}100\text{ }\mu\text{g} 50 – 100 μ g IV ( 0.5 – 1.0 mL 0.5\text{--}1.0\text{ mL} 0.5 – 1.0 mL of 1:10,000 dilution), repeated every 1 to 2 minutes as required.

Grade IV (Cardiac Arrest): 1 mg 1\text{ mg} 1 mg IV boluses every 3 to 5 minutes per ALS algorithm.

Refractory Shock: Continuous infusion of epinephrine at 0.05 – 0.2 μ g/kg/min 0.05\text{--}0.2\text{ }\mu\text{g/kg/min} 0.05 – 0.2 μ g/kg/min .

Aggressive Crystalloid Resuscitation: Up to 35% of intravascular volume extravasates into the interstitial compartment within 10 minutes due to hyperpermeability. Immediately administer 20 – 30 mL/kg 20\text{--}30\text{ mL/kg} 20 – 30 mL/kg of balanced crystalloid ( 1 – 2 L 1\text{--}2\text{ L} 1 – 2 L in adults) under pressure.

Secondary Pharmacotherapy:

Second-line vasopressors: Noradrenaline infusion or vasopressin ( 1 – 2 units 1\text{--}2\text{ units} 1 – 2 units IV) for refractory vasodilatory shock. Glucagon ( 1 – 2 mg 1\text{--}2\text{ mg} 1 – 2 mg IV) is indicated for patients refractory to epinephrine due to chronic beta-blocker therapy.

Inhaled or IV salbutamol for persistent bronchospasm.

Hydrocortisone ( 200 mg 200\text{ mg} 200 mg IV) to blunt delayed biphasic inflammatory reactions (onset 4-8 hours).

Antihistamines: Chlorpheniramine 10 mg 10\text{ mg} 10 mg IV (slow injection).

Diagnostic Immunology: Serum Tryptase Kinetics

Mast cell tryptase is a neutral protease stored in mast cell secretory granules. To substantiate acute mast cell activation, guideline-mandated serial sampling is required:

Sample 1: Collected as soon as feasible once resuscitation is under way (never delay treatment to take it).

Sample 2: Collected ideally 1 – 2 hours 1\text{--}2\text{ hours} 1 – 2 hours after the onset of the reaction, and no later than 4 hours (captures the peak).

Sample 3 (Baseline): Collected at ≥ 24 hours \ge 24\text{ hours} ≥ 24 hours or at outpatient allergy follow-up. Significance Threshold: Peak Tryptase ≥ ( 1.2 × Baseline Tryptase ) + 2 μ g/L \text{Significance Threshold: } \text{Peak Tryptase} \ge (1.2 \times \text{Baseline Tryptase}) + 2\text{ }\mu\text{g/L} Significance Threshold: Peak Tryptase ≥ ( 1.2 × Baseline Tryptase ) + 2 μ g/L

A peak tryptase exceeding this mathematical consensus confirms clinically significant mast cell degranulation. All patients must be formally referred for skin prick and intradermal testing, usually about 4 to 6 weeks after the event.